Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2009 Jan;8(1):23-33. doi: 10.1038/nrd2734. Epub 2008 Dec 12.

Chemokine receptor antagonists: overcoming developmental hurdles.

Author information

  • 1Richard Horuk is an adjunct professor at Touro University, 1310 Johnson Lane, Vallejo, California 94592, USA. Horuk@Pacbell.net

Abstract

Chemokine receptors have a key role in the pathogenesis of autoimmune diseases, inflammation and viral infection. However, with the exception of selective CCR5 antagonists for HIV, the promise of obtaining new therapeutics related to chemokine receptors has not yet been realized. This article highlights some of the recent failures in the clinical trials of chemokine receptor antagonists and explores possible reasons as to why this might have occurred. Such reasons include the lack of predictability of animal models and redundancy of the target. A potential solution could be to develop drugs that target more than one receptor--known as polypharmacology--which could be a novel way to generate effective therapeutics.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk